Arena Pharmaceuticals to Announce Fourth Quarter and Full-Year 2018 Financial Results and Provide Corporate Update on February 26
SAN DIEGO, Feb. 20, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) will announce its fourth quarter and full-year 2018 financial results on Tuesday, February 26, 2019, after the close of the U.S. financial markets. The Company will host a conference call and live webcast to discuss the results with the investment community the same day at 4:30 p.m. EST.
Conference Call & Webcast
Information
When: February 26, 2019,
4:30 p.m. EST
Dial-in: (877) 643-7155 (United States) or (914)
495-8552 (International)
Conference ID: 1855406
Please join the conference call at least 10 minutes early to register. You can access the live webcast under the investor relations section of Arena's website at: www.arenapharm.com. A replay of the conference call will be archived under the investor relations section of Arena's website for 30 days after the call.
About Arena
Pharmaceuticals
Arena Pharmaceuticals is driven to
deliver novel, transformational medicines with optimized
pharmacology and pharmacokinetics to patients globally. Arena's
proprietary pipeline includes multiple potentially first- or
best-in-class assets with broad clinical utility. Etrasimod (APD334), with potential
utility in a broad range of immune and inflammatory conditions, is
being evaluated in later-stage clinical programs in ulcerative
colitis (UC) and Crohn's disease, as well as in programs for other
indications such as atopic dermatitis. Arena is also evaluating
olorinab (APD371) in a Phase 2 program
for gastrointestinal pain. Arena continues to assess other earlier
research and development stage drug candidates, including
APD418 for decompensated heart failure.
Arena's licensee, United Therapeutics, is evaluating ralinepag in a
Phase 3 program for pulmonary arterial hypertension (PAH).
Arena has additional license agreements and partnerships, including with Everest Medicines Limited (etrasimod in Greater China and select Asian countries), Boehringer Ingelheim International GmbH (undisclosed target – preclinical), Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ® – marketed product).
Forward-Looking Statements
Certain
statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such
forward-looking statements include statements about Arena's
upcoming conference call and live webcast with the investment
community, Arena's drive, and the potential of Arena's assets,
programs, collaborations, and licenses. For such statements, Arena
claims the protection of the Private Securities Litigation Reform
Act of 1995. Actual events or results may differ materially from
Arena's expectations. Factors that could cause actual results to
differ materially from the forward-looking statements include those
disclosed in Arena's filings with the Securities and Exchange
Commission. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Corporate
Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
[email protected]
858.210.3636
Media Contact:
Matt Middleman,
MD
LifeSci Public Relations
[email protected]
646.627.8384
View original content to download multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2018-financial-results-and-provide-corporate-update-on-february-26-300799104.html